MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Abstract In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine...

Full description

Bibliographic Details
Main Authors: Leonie Mayer, Leonie M. Weskamm, Anahita Fathi, Maya Kono, Jasmin Heidepriem, Verena Krähling, Sibylle C. Mellinghoff, My Linh Ly, Monika Friedrich, Svenja Hardtke, Saskia Borregaard, Thomas Hesterkamp, Felix F. Loeffler, Asisa Volz, Gerd Sutter, Stephan Becker, Christine Dahlke, Marylyn M. Addo
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-023-00801-z

Internet

https://doi.org/10.1038/s41541-023-00801-z

Similar Items